Hologic, Inc. (HOLX) P/E Ratio History
Premium ValuationTrading at 30.5x vs 5Y avg 23.0x · 75th percentile · Premium to historical baseline · Data 1992–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Hologic, Inc. (HOLX) trades at a price-to-earnings ratio of 30.5x, with a stock price of $76.01 and trailing twelve-month earnings per share of $2.41.
The current P/E is 33% above its 5-year average of 23.0x. Over the past five years, HOLX's P/E has ranged from a low of 8.4x to a high of 42.0x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, HOLX trades at a 38% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, HOLX commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HOLX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HOLX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HOLX P/E vs Peers
Diagnostics and life science tools peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $52B | 24.7 | 1.49 | -1% | |
| $45B | 43.0 | 3.01 | +23% | |
| $28B | 34.7 | 3.31 | +47% | |
| $144B | 51.7 | 2.37 | +23% | |
| $8B | 18.1Lowest | 0.40Best | +437%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HOLX Historical P/E Data (1992–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | Dec 27 2025 | $74.50 | $2.40 | 31.0x | -37% |
| FY2025 Q4 | Sep 27 2025 | $67.21 | $2.48 | 27.1x | -45% |
| FY2025 Q3 | Jun 28 2025 | $65.01 | $2.41 | 27.0x | -46% |
| FY2025 Q2 | Mar 29 2025 | $61.32 | $2.37 | 25.9x | -48% |
| FY2025 Q1 | Dec 28 2024 | $72.60 | $3.17 | 22.9x | -54% |
| FY2024 Q4 | Sep 30 2024 | $81.46 | $3.33 | 24.5x | -51% |
| FY2024 Q3 | Jun 29 2024 | $74.25 | $2.94 | 25.3x | -49% |
| FY2024 Q2 | Mar 30 2024 | $77.96 | $1.96 | 39.8x | -20% |
| FY2024 Q1 | Dec 30 2023 | $71.45 | $2.11 | 33.9x | -32% |
| FY2023 Q4 | Sep 30 2023 | $69.40 | $1.83 | 37.9x | -24% |
| FY2023 Q3 | Jul 01 2023 | $80.97 | $1.93 | 42.0x | -15% |
| FY2023 Q2 | Apr 01 2023 | $80.70 | $2.99 | 27.0x | -46% |
| FY2023 Q1 | Dec 31 2022 | $74.81 | $3.92 | 19.1x | -62% |
| FY2022 Q4 | Sep 30 2022 | $64.52 | $5.12 | 12.6x | -75% |
| FY2022 Q3 | Jun 25 2022 | $70.93 | $5.93 | 12.0x | -76% |
| FY2022 Q2 | Mar 26 2022 | $76.05 | $6.07 | 12.5x | -75% |
| FY2022 Q1 | Dec 25 2021 | $76.12 | $6.65 | 11.4x | -77% |
| FY2021 Q4 | - | $73.81 | $7.20 | 10.3x | -79% |
| FY2021 Q3 | Jun 26 2021 | $65.89 | $7.80 | 8.4x | -83% |
| FY2021 Q2 | Mar 27 2021 | $73.42 | $7.29 | 10.1x | -80% |
| FY2021 Q1 | Dec 26 2020 | $74.77 | $5.27 | 14.2x | -71% |
| FY2020 Q4 | Sep 30 2020 | $66.47 | $4.20 | 15.8x | -68% |
| FY2020 Q3 | Jun 27 2020 | $53.52 | $2.47 | 21.7x | -56% |
| FY2020 Q2 | Mar 28 2020 | $33.26 | $2.29 | 14.5x | -71% |
| FY2020 Q1 | Dec 28 2019 | $52.36 | $0.92 | 56.9x | +15% |
| FY2018 Q1 | Dec 30 2017 | $42.75 | $3.79 | 11.3x | -77% |
| FY2017 Q4 | Sep 30 2017 | $36.69 | $2.64 | 13.9x | -72% |
| FY2017 Q3 | Jul 01 2017 | $45.38 | $2.68 | 16.9x | -66% |
| FY2017 Q2 | Apr 01 2017 | $42.55 | $2.77 | 15.4x | -69% |
| FY2017 Q1 | Dec 31 2016 | $40.12 | $1.17 | 34.3x | -31% |
| FY2016 Q4 | Sep 30 2016 | $38.83 | $1.16 | 33.5x | -33% |
| FY2016 Q3 | Jun 25 2016 | $34.11 | $0.92 | 37.1x | -25% |
| FY2016 Q2 | Mar 26 2016 | $34.35 | $0.72 | 47.7x | -4% |
| FY2016 Q1 | Dec 26 2015 | $39.08 | $0.65 | 60.1x | +21% |
| FY2015 Q4 | Sep 30 2015 | $39.13 | $0.46 | 85.1x | +71% |
| FY2015 Q3 | Jun 27 2015 | $38.25 | $0.47 | 81.4x | +64% |
| FY2015 Q2 | Mar 28 2015 | $32.49 | $0.41 | 79.2x | +60% |
| FY2015 Q1 | Dec 27 2014 | $26.93 | $0.18 | 150.5x | +203% |
| FY2014 Q4 | - | $24.33 | $0.06 | 410.3x | +727% |
| FY2012 Q3 | Jun 23 2012 | $17.71 | $0.12 | 147.6x | +197% |
| FY2012 Q2 | Mar 24 2012 | $21.09 | $0.17 | 124.1x | +150% |
| FY2012 Q1 | Dec 24 2011 | $17.30 | $0.63 | 27.5x | -45% |
| FY2011 Q4 | Sep 30 2011 | $15.21 | $0.59 | 25.8x | -48% |
| FY2010 Q3 | Jun 26 2010 | $14.24 | $0.37 | 38.0x | -23% |
| FY2010 Q2 | Mar 27 2010 | $18.26 | $0.39 | 46.3x | -7% |
| FY2009 Q1 | Dec 27 2008 | $12.39 | $0.05 | 247.8x | +399% |
| FY2007 Q4 | Sep 30 2007 | $30.50 | $0.87 | 35.1x | -29% |
| FY2007 Q3 | Jun 30 2007 | $27.66 | $0.57 | 48.8x | -2% |
| FY2007 Q2 | Mar 31 2007 | $28.82 | $0.47 | 61.8x | +24% |
| FY2007 Q1 | Dec 30 2006 | $23.64 | $0.39 | 61.2x | +23% |
| FY2006 Q4 | Sep 30 2006 | $21.76 | $0.30 | 73.4x | +48% |
| FY2006 Q3 | Jun 24 2006 | $24.00 | $0.41 | 58.5x | +18% |
| FY2006 Q2 | Mar 25 2006 | $27.44 | $0.37 | 74.2x | +49% |
| FY2006 Q1 | Dec 24 2005 | $19.73 | $0.32 | 62.6x | +26% |
| FY2005 Q4 | Sep 30 2005 | $14.44 | $0.31 | 46.6x | -6% |
| FY2005 Q3 | Jun 25 2005 | $9.54 | $0.27 | 35.3x | -29% |
| FY2005 Q2 | Mar 26 2005 | $7.94 | $0.22 | 36.4x | -27% |
| FY2005 Q1 | Dec 25 2004 | $7.03 | $0.18 | 38.4x | -23% |
| FY2004 Q4 | - | $4.82 | $0.14 | 34.3x | -31% |
| FY2004 Q3 | Jun 26 2004 | $5.71 | $0.11 | 51.3x | +3% |
| FY2004 Q2 | Mar 27 2004 | $4.83 | $0.09 | 56.0x | +13% |
| FY2004 Q1 | Dec 27 2003 | $4.28 | $0.06 | 69.7x | +40% |
| FY2003 Q4 | - | $3.40 | $0.04 | 91.6x | +85% |
| FY2003 Q1 | Dec 28 2002 | $3.19 | $0.01 | 295.4x | +495% |
| FY1999 Q3 | Jun 26 1999 | $1.41 | $0.01 | 103.4x | +108% |
| FY1999 Q2 | Mar 27 1999 | $2.19 | $0.12 | 18.4x | -63% |
| FY1999 Q1 | Dec 26 1998 | $3.00 | $0.19 | 15.9x | -68% |
| FY1998 Q4 | Sep 30 1998 | $3.25 | $0.19 | 17.2x | -65% |
| FY1998 Q3 | Jun 27 1998 | $4.59 | $0.23 | 19.8x | -60% |
| FY1998 Q2 | Mar 28 1998 | $7.13 | $0.24 | 29.4x | -41% |
| FY1998 Q1 | Dec 27 1997 | $5.25 | $0.28 | 18.9x | -62% |
| FY1997 Q4 | - | $7.02 | $0.32 | 21.9x | -56% |
| FY1997 Q3 | Jun 28 1997 | $6.63 | $0.29 | 22.8x | -54% |
| FY1997 Q2 | Mar 29 1997 | $6.00 | $0.28 | 21.2x | -57% |
| FY1997 Q1 | Dec 28 1996 | $6.19 | $0.27 | 23.3x | -53% |
| FY1996 Q4 | Sep 30 1996 | $7.00 | $0.22 | 31.7x | -36% |
| FY1996 Q3 | Jun 29 1996 | $11.06 | $0.20 | 56.2x | +13% |
| FY1996 Q2 | Mar 30 1996 | $5.69 | $0.13 | 43.2x | -13% |
| FY1996 Q1 | Dec 30 1995 | $5.13 | $0.07 | 74.1x | +49% |
| FY1995 Q4 | Sep 30 1995 | $2.88 | $0.05 | 53.0x | +7% |
| FY1995 Q3 | Jun 24 1995 | $2.13 | $0.05 | 38.9x | -22% |
| FY1995 Q2 | Mar 25 1995 | $1.75 | $0.07 | 23.5x | -53% |
| FY1995 Q1 | Dec 31 1994 | $1.88 | $0.10 | 19.3x | -61% |
| FY1994 Q4 | Sep 30 1994 | $1.95 | $0.09 | 21.8x | -56% |
| FY1994 Q3 | - | $1.34 | $0.05 | 26.9x | -46% |
| FY1994 Q2 | - | $0.86 | $0.01 | 85.9x | +73% |
| FY1993 Q3 | Jun 30 1993 | $0.56 | $0.03 | 17.3x | -65% |
| FY1992 Q4 | Sep 30 1992 | $0.77 | $0.05 | 16.1x | -68% |
Average P/E for displayed period: 49.6x
Full Stock Analysis
Deep dive into HOLX consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
34+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HOLX — Frequently Asked Questions
Quick answers to the most common questions about buying HOLX stock.
What is HOLX's P/E ratio?
Hologic, Inc. (HOLX) trailing twelve-month P/E ratio is 30.5x, based on TTM diluted EPS of $2.41. The 5-year average P/E is 23.0x and the historical range spans 8.4x to 42.0x.
Is HOLX stock overvalued or undervalued?
HOLX trades at 30.5x P/E, above its 5-year average of 23.0x. The 75th percentile ranking within the 8.4x–42.0x historical range indicates a premium to historical valuation.
Is HOLX stock expensive?
Yes, HOLX is expensive relative to its own history. The current P/E of 30.5x is above the 5-year average of 23.0x and also above the Healthcare sector median of 22.1x. The stock sits at the 75th percentile of its 5-year valuation range.
What is HOLX's historical P/E range?
Over the past 5 years, HOLX's P/E ratio has ranged from 8.4x to 42.0x, with a median of 25.3x and an average of 23.0x. The current P/E of 30.5x places the stock at the 75th percentile of this range. Full historical data spans 1992–2026.
How does HOLX's P/E compare to the S&P 500?
HOLX trades at 30.5x P/E versus the S&P 500 median of 24.4x. The 25% premium to the market typically reflects higher expected earnings growth or quality.
How does HOLX's valuation compare to Healthcare peers?
Hologic, Inc. P/E of 30.5x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is HOLX's PEG ratio?
HOLX PEG ratio is N/A, based on a P/E of 30.5x and EPS growth of -25.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is HOLX's earnings yield?
HOLX earnings yield is 3.28%, the inverse of its 30.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.